Predictors of symptomatic HIV-associated neurocognitive disorders in universal health care

HIV Medicine

Volumn 14, Issue 2, 2013, Pages 99-107

  Mccombe, Ja ^a,c   Vivithanaporn, P ^a,b   Gill, Mj ^c,d,e   Power, C ^a,c,d  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Mahidol University   (Thailand)

^c Southern Alberta Clinic   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e UNIVERSITY OF CALGARY   (Canada)

Author keywords

HIV; HIV associated dementia; HIV associated neurocognitive disorder

Indexed keywords

VIRUS RNA;

ADULT; AFRICA; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CLINICAL FEATURE; DEMOGRAPHY; ETHNICITY; FEMALE; HEALTH CARE ACCESS; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PREDICTIVE VALUE; PRIORITY JOURNAL; SMOKING; SURVIVAL TIME; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AIDS DEMENTIA COMPLEX; ANTI-HIV AGENTS; CANADA; CD4 LYMPHOCYTE COUNT; COGNITION DISORDERS; COHORT STUDIES; FEMALE; HEPATITIS C; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; VIRAL LOAD;

EID: 84871934278     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2012.01043.x     Document Type: Article

References (40)

1. Cysique LA, Maruff P, Brew BJ. Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts. J Neurovirol 2004; 10: 350-357.
2. Dore GJ, McDonald A, Li Y, Kaldor JM, Brew BJ, National HIV Surveillance C. Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 2003; 17: 1539-1545.
3. Simioni S, Cavassini M, Annoni JM etal. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010; 24: 1243-1250.
4. Pumpradit W, Ananworanich J, Lolak S etal. Southeast Asia Research Collaboration with Hawaii (SEARCH) 005 Protocol Team. Neurocognitive impairment and psychiatric comorbidity in well-controlled human immunodeficiency virus-infected thais from the 2NN cohort study. J Neurovirol 2010; 16: 76-82.
5. Lawler K, Mosepele M, Ratcliffe S etal. Neurocognitive impairment among HIV-positive individuals in Botswana: a pilot study. Journal of the International AIDS Society 2010; 13: 15.
6. Joska JA, Gouse H, Paul RH, Stein DJ, Flisher AJ. Does highly active antiretroviral therapy improve neurocognitive function? A systematic review. J Neurovirol 2010; 16: 101-114.
7. Vivithanaporn P, Heo G, Gamble J etal. Neurologic disease burden in treated HIV/AIDS predicts survival: a population-based study. Neurology 2010; 75: 1150-1158.
8. Childs EA, Lyles RH, Selnes OA etal. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology 1999; 52: 607-613.
9. Dore GJ, Correll PK, Li Y, Kaldor JM, Cooper DA, Brew BJ. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 1999; 13: 1249-1253.
10. Sacktor N, McDermott MP, Marder K etal. HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 2002; 8: 136-142.
11. Heaton RK, Clifford DB, Franklin DR, Jr etal. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy. Neurology 2010; 75: 2087-2096.
12. Valcour V, Shikuma C, Shiramizu B etal. Higher frequency of dementia in older HIV-1 individuals: the Hawaii aging with HIV-1 cohort. Neurology 2004; 63: 822-827.
13. Cherner M, Ellis RJ, Lazzaretto D etal. Effects of HIV-1 infection and aging on neurobehavioral functioning: preliminary findings. AIDS 2004; 18 (Suppl 1): S27-S34.
14. Bhaskaran K, Mussini C, Antinori A etal. Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Ann Neurol 2008; 63: 213-221.
15. Jevtovic D, Vanovac V, Veselinovic M, Salemovic D, Ranin J, Stefanova E. The incidence of and risk factors for HIV-associated cognitive-motor complex among patients on HAART. Biomed Pharmacother 2009; 63: 561-565.
16. Letendre SL, Cherner M, Ellis RJ etal. The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: biological correlates of disease. AIDS 2005; 19 (Suppl 3): S72-S78.
17. Ryan EL, Morgello S, Isaacs K, Naseer M, Gerits P, Manhattan HIV Brain B. Neuropsychiatric impact of hepatitis C on advanced HIV. Neurology 2004; 62: 957-962.
18. Tozzi V, Balestra P, Lorenzini P etal. Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohort. J Neurovirol 2005; 11: 265-273.
19. Parsons TD, Tucker KA, Hall CD etal. Neurocognitive functioning and HAART in HIV and hepatitis C virus co-infection. AIDS 2006; 20: 1591-1595.
20. Thiyagarajan A, Garvey LJ, Pflugrad H etal. Cerebral function tests reveal differences in HIV-infected subjects with and without chronic HCV co-infection. Clin Microbiol Infect 2010; 16: 1579-1584.
21. Chiesi A, Vella S, Dally LG etal. Epidemiology of AIDS dementia complex in Europe. AIDS in Europe study group. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 11: 39-44.
22. Valcour VG, Shikuma CM, Shiramizu BT etal. Diabetes, insulin resistance, and dementia among HIV-1-infected patients. J Acquir Immune Defic Syndr 2005; 38: 31-36.
23. Wright EJ, Grund B, Robertson K etal. Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology 2010; 75: 864-873.
24. Foley J, Ettenhofer M, Wright MJ etal. Neurocognitive functioning in HIV-1 infection: effects of cerebrovascular risk factors and age. Clin Neuropsychol 2010; 24: 265-285.
25. Liner KJ, 2nd, Hall CD, Robertson KR. Impact of human immunodeficiency virus (HIV) subtypes on HIV-associated neurological disease. J Neurovirol 2007; 13: 291-304.
26. Teja VD, Talasila SR, Vemu L. Neurologic manifestations of HIV infection: an Indian hospital-based study. AIDS Read 2005; 15: 139-143.
27. Wadia RS, Pujari SN, Kothari S etal. Neurological manifestations of HIV disease. J Assoc Physicians India 2001; 49: 343-348.
28. Gupta JD, Satishchandra P, Gopukumar K etal. Neuropsychological deficits in human immunodeficiency virus type 1 clade C-seropositive adults from south India. J Neurovirol 2007; 13: 195-202.
29. Njamnshi AK, Bissek AC, Ongolo-Zogo P etal. Risk factors for HIV-associated neurocognitive disorders (HAND) in sub-Saharan Africa: the case of Yaounde-Cameroon. J Neurol Sci 2009; 285: 149-153.
30. Patel VN, Mungwira RG, Tarumbiswa TF, Heikinheimo T, van Oosterhout JJ. High prevalence of suspected HIV-associated dementia in adult malawian HIV patients. Int J STD AIDS 2010; 21: 356-358.
31. Robinson-Papp J, Byrd D, Mindt MR etal. Motor function and human immunodeficiency virus-associated cognitive impairment in a highly active antiretroviral therapy-era cohort. Arch Neurol 2008; 65: 1096-1101.
32. Valcour VG, Shiramizu BT, Sithinamsuwan P etal. HIV DNA and cognition in a Thai longitudinal HAART initiation cohort: the SEARCH 001 cohort study. Neurology 2009; 72: 992-998.
33. Modi G, Hari K, Modi M, Mochan A. The frequency and profile of neurology in black south african HIV infected (clade C) patients - a hospital-based prospective audit. J Neurol Sci 2007; 254: 60-64.
34. Becker JT, Kingsley L, Mullen J etal. Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men. Neurology 2009; 73: 1292-1299.
35. Kitahata MM, Gange SJ, Abraham AG etal. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360: 1815-1826.
36. McCombe JA, Acharjee S, Gill MJ, Power C. Viral and host genetic factors. In: Gendelman HE, Grant I, Everall IP etal., eds. The Neurology of AIDS. 3rd Edition. New York: Oxford University Press, 2011: 50-70.
37. Nath A. Human immunodeficiency virus-associated neurocognitive disorder: pathophysiology in relation to drug addiction. Ann N Y Acad Sci 2010; 1187: 122-128.
38. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006; 20: W13-W23.
39. Mahadevan A, Shankar SK, Satishchandra P etal. Characterization of human immunodeficiency virus (HIV)-infected cells in infiltrates associated with CNS opportunistic infections in patients with HIV clade C infection. J Neuropathol Exp Neurol 2007; 66: 799-808.
40. Sacktor N, Nakasujja N, Skolasky RL etal. HIV subtype D is associated with dementia, compared with subtype A, in immunosuppressed individuals at risk of cognitive impairment in Kampala, Uganda. Clin Infect Dis 2009; 49: 780-786.